COMPARISON OF MEAN DURATION OF POST OPERATIVE ANALGESIA FOLLOWING ADDITION OF DEXMEDETOMIDINE TO ROPIVACAINE VERSUS PLAIN ROPIVACAINE ON ULTRASOUND GUIDED RECTUS SHEATH BLOCK
COMPARISON OF MEAN DURATION OF POST OPERATIVE ANALGESIA FOLLOWING ADDITION OF DEXMEDETOMIDINE TO ROPIVACAINE VERSUS PLAIN ROPIVACAINE ON ULTRASOUND GUIDED RECTUS SHEATH BLOCK IN PATIENTS UNDERGOING MIDLINE LAPAROTOMIES
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab Province
-
Bahawalpur, Punjab Province, Pakistan, 63100
- Bahawal Victoria Hospital, Bahawalpur
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with age 30 - 60 years.
- Patients that will be scheduled for laparotomy under general anesthesia.
- ASA (American Society of Anesthesiologist) s
Exclusion Criteria:
- Patient who will refuse for participation in study.
- Infection at site of Rectus Sheath block.
- History of any addiction.
- Sensitivity to the local anesthetics.
- Patient with pre-existing coagulation abnormalities INR more than 1.5.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Ropivacaine only group
|
In Dexmedetomedine combined with ropivacaine group, under ultrasound guidance, the needle will be advanced posterior to the rectus muscle, and 20 ml of 0.25% ropivacaine mixed with 1ug/kg body weight will be injected to hydrodissect the rectus muscle from the posterior sheath. In ropivacine only group, under ultrasound guidance, the needle will be advanced posterior to the rectus muscle, and 20 ml of 0.25% ropivacaine will be injected to hydrodissect the rectus muscle from the posterior sheath. |
|
Active Comparator: Dexmedetomedine combined with ropivacaine group
|
In Dexmedetomedine combined with ropivacaine group, under ultrasound guidance, the needle will be advanced posterior to the rectus muscle, and 20 ml of 0.25% ropivacaine mixed with 1ug/kg body weight will be injected to hydrodissect the rectus muscle from the posterior sheath. In ropivacine only group, under ultrasound guidance, the needle will be advanced posterior to the rectus muscle, and 20 ml of 0.25% ropivacaine will be injected to hydrodissect the rectus muscle from the posterior sheath. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean duration of analgesia
Time Frame: Baseline , 30 minutes , 2 hours, 4 hours , 6 hours , 8 hours , 12 hours , 24 hours
|
Assessed using the visual analogue score(VAS) ranging from 0-10 (0=no pain , 10= most severe unbearable pain)
|
Baseline , 30 minutes , 2 hours, 4 hours , 6 hours , 8 hours , 12 hours , 24 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- BVH-2025-CT-012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.